A regression framework for a probabilistic measure of cost-effectiveness.

To make informed health policy decisions regarding a treatment, we must consider both its cost and its clinical effectiveness. In past work, we introduced the net benefit separation (NBS) as a novel measure of cost-effectiveness. The NBS is a probabilistic measure that characterizes the extent to which a treated patient will be more likely to experience benefit as compared to an untreated patient. Due to variation in treatment response across patients, uncovering factors that influence cost-effectiveness can assist policy makers in population-level decisions regarding resource allocation. In this paper, we introduce a regression framework for NBS in order to estimate covariate-specific NBS and find determinants of variation in NBS. Our approach is able to accommodate informative cost censoring through inverse probability weighting techniques, and addresses confounding through a semiparametric standardization procedure. Through simulations, we show that NBS regression performs well in a variety of common scenarios. We apply our proposed regression procedure to a realistic simulated data set as an illustration of how our approach could be used to investigate the association between cancer stage, comorbidities and cost-effectiveness when comparing adjuvant radiation therapy and chemotherapy in post-hysterectomy endometrial cancer

[1]  S. Bae,et al.  International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? , 2010, Health economics.

[2]  Anastasios A. Tsiatis,et al.  Estimating medical costs with censored data , 2000 .

[3]  E. Feuer,et al.  Estimating medical costs from incomplete follow-up data. , 1997, Biometrics.

[4]  M. J. van der Laan,et al.  Statistical Applications in Genetics and Molecular Biology Super Learner , 2010 .

[5]  A. Haggerty,et al.  Adjuvant therapy in early-stage endometrial cancer: a systematic review of the evidence, guidelines, and clinical practice in the U.S. , 2014, The oncologist.

[6]  Andrew R Willan,et al.  Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. , 2004, Health economics.

[7]  Nobuyuki Susumu,et al.  Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. , 2008, Gynecologic oncology.

[8]  J. Hanley.  The Robustness of the "Binormal" Assumptions Used in Fitting ROC Curves , 1988, Medical decision making : an international journal of the Society for Medical Decision Making.

[9]  Nicholas Illenberger,et al.  Net benefit separation and the determination curve: A probabilistic framework for cost-effectiveness estimation , 2019, Statistical methods in medical research.

[10]  Margaret S. Pepe,et al.  A regression modelling framework for receiver operating characteristic curves in medical diagnostic testing , 1997 .

[11]  John Mullahy,et al.  Net Health Benefits: A New Framework for the Analysis of Uncertainty in Cost-Effectiveness Analysis , 1998 .

[12]  Margaret Sullivan Pepe,et al.  Distribution-free ROC analysis using binary regression techniques. , 2002, Biostatistics.

[13]  Arman Oganisian,et al.  A causal approach to analysis of censored medical costs in the presence of time-varying treatment , 2017 .

[14]  Eric J Feuer,et al.  Projections of the cost of cancer care in the United States: 2010-2020. , 2011, Journal of the National Cancer Institute.

[15]  Nandita Mitra,et al.  Analyzing medical costs with time‐dependent treatment: The nested g‐formula , 2018, Health economics.

[16]  Simon G Thompson,et al.  Methods for incorporating covariate adjustment, subgroup analysis and between-centre differences into cost-effectiveness evaluations. , 2005, Health economics.

[17]  M. Pepe.  An Interpretation for the ROC Curve and Inference Using GLM Procedures , 2000, Biometrics.

[18]  J. Gold,et al.  Validation of a combined comorbidity index. , 1994, Journal of clinical epidemiology.

[19]  Nandita Mitra,et al.  A doubly robust approach for cost–effectiveness estimation from observational data , 2018, Statistical methods in medical research.

[20]  Robert Piessens,et al.  Quadpack: A Subroutine Package for Automatic Integration , 2011 .

[21]  J. Roy,et al.  A Bayesian nonparametric model for zero‐inflated outcomes: Prediction, clustering, and causal estimation , 2018, Biometrics.

[22]  M. Randall,et al.  Adjuvant radiotherapy in endometrial carcinoma. , 2005, The oncologist.

[23]  R. Koenker,et al.  Regression Quantiles , 2007 .